Shots:
- Sanofi became the Nuvaxovid market authorization holder in Canada to supply the protein-based COVID-19 vaccine. Nuvaxovid to be available in Canada for the fall 2026-2027 season
- Authorization was supported by pivotal P-III trials demonstrating ~90% efficacy of Nuvaxovid in preventing symptomatic COVID-19. Demonstrated a favourable tolerability profile, supporting its use for seasonal vaccination
- Nuvaxovid is a non-mRNA, protein-based vaccine for active immunization against COVID-19 in individuals aged ≥12 years. Market authorization transfer from Novavax followed a strategic agreement signed in May 2024
Ref: Newswire.CA | Image: Sanofi | Press Release
Related News: Novavax’s Nuvaxovid Receives the US FDA Approval for Active Immunization against COVID-19
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
